Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2008

View Archived Issues

New agents for arthritis and other antiinflammatory conditions reported in recent patents

Novel analgesic agents reported in recent patent literature

Recent Biovitrum patent describes novel antiobesity agents

Treanda receives FDA approval for CLL

RXR agonist NRX-4204 begins phase I trial

CHMP recommends approval of Zevalin as first-line consolidation therapy

Medicago's H5N1 vaccine protects against multiple strains of avian flu

Ceragenix and FirstPoint enter license agreement for CSA-54 in HIV

Pivotal diabetes study of mitiglinide completes enrollment

FDA clears Third Wave's InPlex molecular test for cystic fibrosis

Corcept initiates phase III trial of Corlux for the psychotic features of psychotic depression

Depomed initiates dosing in phase III clinical trial of Gabapentin GR in postherpetic neuralgia

CHMP rejects UCB's appeal over refusal of E.U. MAA for Cimzia in Crohn's disease

NanoBio reports promising results from phase II study of NB-002 for onychomycosis

FDA grants clearance to ProNAi to initiate phase I clinical trials of PNT-2258 for cancer

Acceleron and Celgene receive Hart-Scott-Rodino clearance for ACE-011 collaboration

SIGA Technologies submits EUA application to the FDA for smallpox antiviral ST-246

BioLineRx reports results from phase I/II clinical trial of BL-1040 for acute MI

Thyroid-stimulating hormone reverses ovariectomy-induced bone loss in rats

JNJ-27390467, a novel tryptase inhibitor with efficacy in models of allergic asthma

Novel CCR5 antagonist profiled at Novartis

Repligen commences phase III RG-1068 trial for pancreatic MRI imaging

FDA approves IND application for use of Davanat to treat a breast cancer patient

Presidio obtains exclusive worldwide rights to XTL's NS5A program for HCV

Sosei to temporarily halt AD-923 phase III studies in cancer breakthrough pain

First Committee on New Drugs passes AnGes' NDA for Naglazyme for MPS VI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...